Top

Published in:

01-06-2020 | Mood Disorders | Clinical trial

Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

Authors: Karin Ribi, Weixiu Luo, Barbara A. Walley, Harold J. Burstein, Jacquie Chirgwin, Rafat H. Ansari, Muhammed Salim, Andre van der Westhuizen, Ehtesham Abdi, Prudence A. Francis, Stephen Chia, Vernon J. Harvey, Anita Giobbie-Hurder, Gini F. Fleming, Olivia Pagani, Angelo Di Leo, Marco Colleoni, Richard D. Gelber, Aron Goldhirsch, Alan S. Coates, Meredith M. Regan, Jürg Bernhard

Published in: Breast Cancer Research and Treatment | Issue 2/2020

Abstract

Purpose

Sexual dysfunction is an important concern of premenopausal women with early breast cancer. We investigated predictors of sexual problems in two randomized controlled trials.

Methods

A subset of patients enrolled in TEXT and SOFT completed global and symptom-specific quality-of-life indicators, CES-Depression and MOS-Sexual Problems measures at baseline, six, 12 and 24 months. Mixed models tested the association of changes in treatment-induced symptoms (baseline to 6 months), depression at 6 months, and age at randomization with changes in sexual problems over 2 years.

Results

Sexual problems increased by 6 months and persisted at this level. Overall, patients with more severe worsening of vaginal dryness, sleep disturbances and bone or joint pain at 6 months reported a greater increase in sexual problems at all time-points. Depression scores were significantly associated with sexual problems in the short-term. All other symptoms had a smaller impact on sexual problems. Age was not associated with sexual problems at any time-point.

Conclusion

Among several key symptoms, vaginal dryness, sleep disturbance, and bone and joint pain significantly predicted sexual problems during the first 2 years. Early identification of these symptoms may contribute to timely and tailored interventions.

Available only for authorised users

Bober SL, Varela VS (2012) Sexuality in adult cancer survivors: challenges and intervention. J Clin Oncol 30(30):3712–3719. https://doi.org/10.1200/JCO.2012.41.7915 CrossRefPubMed

Schover LR, van der Kaaij M, van Dorst E, Creutzberg C, Huyghe E, Kiserud CE (2014) Sexual dysfunction and infertility as late effects of cancer treatment. EJC Suppl 12(1):41–53. https://doi.org/10.1016/j.ejcsup.2014.03.004 CrossRefPubMedPubMedCentral

Kedde H, van de Wiel HB, Weijmar Schultz WC, Wijsen C (2013) Sexual dysfunction in young women with breast cancer. Support Care Cancer 21(1):271–280. https://doi.org/10.1007/s00520-012-1521-9 CrossRefPubMed

Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS (2013) Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 20(2):162–168. https://doi.org/10.1097/gme.0b013e31826560da CrossRefPubMed

Frechette D, Paquet L, Verma S, Clemons M, Wheatley-Price P, Gertler SZ, Song X, Graham N, Dent S (2013) The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study. Breast Cancer Res Treat 141(1):111–117. https://doi.org/10.1007/s10549-013-2659-y CrossRefPubMed

Raggio GA, Butryn ML, Arigo D, Mikorski R, Palmer SC (2014) Prevalence and correlates of sexual morbidity in long-term breast cancer survivors. Psychol Health 29(6):632–650. https://doi.org/10.1080/08870446.2013.879136 CrossRefPubMedPubMedCentral

Maiorino MI, Chiodini P, Bellastella G, Giugliano D, Esposito K (2016) Sexual dysfunction in women with cancer: a systematic review with meta-analysis of studies using the Female Sexual Function Index. Endocrine 54(2):329–341. https://doi.org/10.1007/s12020-015-0812-6 CrossRefPubMed

Davis SR, Panjari M, Robinson PJ, Fradkin P, Bell RJ (2014) Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis. Menopause 21(10):1075–1081. https://doi.org/10.1097/GME.0000000000000219 CrossRefPubMed

Oberguggenberger A, Martini C, Huber N, Fallowfield L, Hubalek M, Daniaux M, Sperner-Unterweger B, Holzner B, Sztankay M, Gamper E, Meraner V (2017) Self-reported sexual health: breast cancer survivors compared to women from the general population—an observational study. BMC Cancer 17(1):599. https://doi.org/10.1186/s12885-017-3580-2 CrossRefPubMedPubMedCentral

10.

Aerts L, Christiaens MR, Enzlin P, Neven P, Amant F (2014) Sexual functioning in women after mastectomy versus breast conserving therapy for early-stage breast cancer: a prospective controlled study. Breast 23(5):629–636. https://doi.org/10.1016/j.breast.2014.06.012 CrossRefPubMed

11.

Boquiren VM, Esplen MJ, Wong J, Toner B, Warner E, Malik N (2016) Sexual functioning in breast cancer survivors experiencing body image disturbance. Psychooncology 25(1):66–76. https://doi.org/10.1002/pon.3819 CrossRefPubMed

12.

Schover LR (2008) Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol 26(5):753–758. https://doi.org/10.1200/JCO.2007.14.1655 CrossRefPubMed

13.

Rosenberg SM, Tamimi RM, Gelber S, Ruddy KJ, Bober SL, Kereakoglow S, Borges VF, Come SE, Schapira L, Partridge AH (2014) Treatment-related amenorrhea and sexual functioning in young breast cancer survivors. Cancer 120(15):2264–2271. https://doi.org/10.1002/cncr.28738 CrossRefPubMedPubMedCentral

14.

Berglund G, Nystedt M, Bolund C, Sjoden PO, Rutquist LE (2001) Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol 19(11):2788–2796. https://doi.org/10.1200/JCO.2001.19.11.2788 CrossRefPubMed

15.

Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Puglisi F, Pavesi L, Parmar V, Regan MM, Pagani O, Fleming GF, Francis PA, Price KN, Coates AS, Gelber RD, Goldhirsch A, Walley BA (2015) Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol 16(7):848–858. https://doi.org/10.1016/S1470-2045(15)00049-2 CrossRefPubMedPubMedCentral

16.

Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, Martino S, Ingle JN, Sparano JA, Solin LJ, Wood WC, Robert NJ (2014) Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 32(35):3948–3958. https://doi.org/10.1200/JCO.2014.55.6993 CrossRefPubMedPubMedCentral

17.

Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Kerbrat P, Perello A, Neven P, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates AS, Goldhirsch A, Price KN, Gelber RD, Regan MM, Fleming GF (2016) Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol 34(14):1601–1610. https://doi.org/10.1200/JCO.2015.64.8675 CrossRefPubMedPubMedCentral

18.

Avis NE, Johnson A, Canzona MR, Levine BJ (2018) Sexual functioning among early post-treatment breast cancer survivors. Support Care Cancer 26(8):2605–2613. https://doi.org/10.1007/s00520-018-4098-0 CrossRefPubMedPubMedCentral

19.

Lee M, Kim YH, Jeon MJ (2015) Risk factors for negative impacts on sexual activity and function in younger breast cancer survivors. Psychooncology 24(9):1097–1103. https://doi.org/10.1002/pon.3772 CrossRefPubMed

20.

Speer JJ, Hillenberg B, Sugrue DP, Blacker C, Kresge CL, Decker VB, Zakalik D, Decker DA (2005) Study of sexual functioning determinants in breast cancer survivors. Breast J 11(6):440–447. https://doi.org/10.1111/j.1075-122X.2005.00131.x CrossRefPubMed

21.

Bredart A, Dolbeault S, Savignoni A, Besancenet C, This P, Giami A, Michaels S, Flahault C, Falcou MC, Asselain B, Copel L (2011) Prevalence and associated factors of sexual problems after early-stage breast cancer treatment: results of a French exploratory survey. Psychooncology 20(8):841–850. https://doi.org/10.1002/pon.1789 CrossRefPubMed

22.

Landi SN, Doll KM, Bensen JT, Hendrix L, Anders CK, Wu JM, Nichols HB (2016) Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis. Cancer Causes Control 27(11):1325–1332. https://doi.org/10.1007/s10552-016-0810-x CrossRefPubMedPubMedCentral

23.

Soldera SV, Ennis M, Lohmann AE, Goodwin PJ (2018) Sexual health in long-term breast cancer survivors. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-018-4894-8 CrossRefPubMed

24.

Perez M, Liu Y, Schootman M, Aft RL, Schechtman KB, Gillanders WE, Jeffe DB (2010) Changes in sexual problems over time in women with and without early-stage breast cancer. Menopause 17(5):924–937. https://doi.org/10.1097/gme.0b013e3181d5dd26 CrossRefPubMedPubMedCentral

25.

Marino JL, Saunders CM, Emery LI, Green H, Doherty DA, Hickey M (2016) How does adjuvant chemotherapy affect menopausal symptoms, sexual function, and quality of life after breast cancer? Menopause 23(9):1000–1008. https://doi.org/10.1097/GME.0000000000000664 CrossRefPubMed

26.

Panjari M, Bell RJ, Davis SR (2011) Sexual function after breast cancer. J Sex Med 8(1):294–302. https://doi.org/10.1111/j.1743-6109.2010.02034.x CrossRefPubMed

27.

van Londen GJ, Beckjord EB, Dew MA, Cooper KL, Davidson NE, Bovbjerg DH, Donovan HS, Thurston RC, Morse JQ, Nutt S, Rechis R (2014) Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors. Support Care Cancer 22(4):937–945. https://doi.org/10.1007/s00520-013-2041-y CrossRefPubMed

28.

Hummel SB, Hahn DEE, van Lankveld J, Oldenburg HSA, Broomans E, Aaronson NK (2017) Factors associated with specific diagnostic and statistical manual of mental disorders, fourth edition sexual dysfunctions in breast cancer survivors: a study of patients and their partners. J Sex Med 14(10):1248–1259. https://doi.org/10.1016/j.jsxm.2017.08.004 CrossRefPubMed

29.

Robinson PJ, Bell RJ, Christakis MK, Ivezic SR, Davis SR (2017) Aromatase inhibitors are associated with low sexual desire causing distress and fecal incontinence in women: an observational study. J Sex Med 14(12):1566–1574. https://doi.org/10.1016/j.jsxm.2017.09.018 CrossRefPubMed

30.

Gandhi C, Butler E, Pesek S, Kwait R, Edmonson D, Raker C, Clark MA, Stuckey A, Gass J (2019) Sexual dysfunction in breast cancer survivors: is it surgical modality or adjuvant therapy? Am J Clin Oncol 42(6):500–506. https://doi.org/10.1097/COC.0000000000000552 CrossRefPubMed

31.

Burwell SR, Case LD, Kaelin C, Avis NE (2006) Sexual problems in younger women after breast cancer surgery. J Clin Oncol 24(18):2815–2821. https://doi.org/10.1200/JCO.2005.04.2499 CrossRefPubMed

32.

Paiva CE, Rezende FF, Paiva BS, Mauad EC, Zucca-Matthes G, Carneseca EC, Syrjanen KJ, Schover LR (2016) Associations of body mass index and physical activity with sexual dysfunction in breast cancer survivors. Arch Sex Behav 45:2057–2068. https://doi.org/10.1007/s10508-016-0758-7 CrossRefPubMed

33.

Rojas KE, Matthews N, Raker C, Clark MA, Onstad M, Stuckey A, Gass J (2018) Body mass index (BMI), postoperative appearance satisfaction, and sexual function in breast cancer survivorship. J Cancer Surviv 12(1):127–133. https://doi.org/10.1007/s11764-017-0651-y CrossRefPubMed

34.

Den Oudsten BL, Van Heck GL, Van der Steeg AF, Roukema JA, De Vries J (2010) Clinical factors are not the best predictors of quality of sexual life and sexual functioning in women with early stage breast cancer. Psychooncology 19(6):646–656. https://doi.org/10.1002/pon.1610 CrossRef

35.

Morrow PK, Broxson AC, Munsell MF, Basen-Enquist K, Rosenblum CK, Schover LR, Nguyen LH, Hsu L, Castillo L, Hahn KM, Litton JK, Kwiatkowski DN, Hortobagyi GN (2014) Effect of age and race on quality of life in young breast cancer survivors. Clin Breast Cancer 14(2):e21–31. https://doi.org/10.1016/j.clbc.2013.10.003 CrossRefPubMed

36.

Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, TEXT, and SOFT Investigators; International Breast Cancer Study Group (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371(2):107–118. https://doi.org/10.1056/NEJMoa1404037 CrossRefPubMedPubMedCentral

37.

Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD, SOFT Investigators; International Breast Cancer Study Group (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372(5):436–446. https://doi.org/10.1056/NEJMoa1412379 CrossRefPubMed

38.

Sherbourne CD (1992) Social functioning: sexual problems measures. In: Stewart AL, Ware JE (eds) Measuring functioning and well-being: the medical outcomes study approach. Duke University Press, Durham, pp 194–204

39.

Bartula I, Sherman KA (2013) Screening for sexual dysfunction in women diagnosed with breast cancer: systematic review and recommendations. Breast Cancer Res Treat 141(2):173–185. https://doi.org/10.1007/s10549-013-2685-9 CrossRefPubMedPubMedCentral

40.

Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N (2016) Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387(10021):857–865. https://doi.org/10.1016/S0140-6736(15)01169-1 CrossRefPubMed

41.

Sloan JA, Dueck A (2004) Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 14(1):73–96. https://doi.org/10.1081/BIP-120028507 CrossRefPubMed

42.

Bernhard J, Hurny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Senn HJ, Rudenstam CM (1997) Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group. Ann Oncol 8(9):825–835. https://doi.org/10.1023/A:1008269715091 CrossRefPubMed

43.

Bernhard J, Sullivan M, Hurny C, Coates AS, Rudenstam CM (2001) Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer 84(9):1156–1165. https://doi.org/10.1054/bjoc.2001.1785 CrossRefPubMedPubMedCentral

44.

Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hurny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Thurlimann B, Price KN, Goldhirsch A, Coates AS, International Breast Cancer Study Group Trial V (2007) Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients—the International Breast Cancer Study Group Trial VIII. J Clin Oncol 25(3):263–270. https://doi.org/10.1200/JCO.2005.04.5393 CrossRef

45.

Radloff LS (1977) The CES-D Scale: a self-reported depression scale for research in the general population. Appl Psychol Meas 1:385–401CrossRef

46.

Wakefield CE, Butow PN, Aaronson NA, Hack TF, Hulbert-Williams NJ, Jacobsen PB, International Psycho-Oncology Society Research Committee (2015) Patient-reported depression measures in cancer: a meta-review. Lancet Psychiatry 2(7):635–647. https://doi.org/10.1016/S2215-0366(15)00168-6 CrossRefPubMed

47.

von Hippel C, Rosenberg SM, Austin SB, Sprunck-Harrild K, Ruddy KJ, Schapira L, Come S, Borges VF, Partridge AH (2019) Identifying distinct trajectories of change in young breast cancer survivors' sexual functioning. Psychooncology 28(5):1033–1040. https://doi.org/10.1002/pon.5047 CrossRef

48.

Ganz PA, Desmond KA, Belin TR, Meyerowitz BE, Rowland JH (1999) Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 17(8):2371–2380. https://doi.org/10.1200/JCO.1999.17.8.2371 CrossRefPubMed

49.

Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, Hershman DL, Wade JL 3rd (2018) Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. J Clin Oncol 36(4):326–332. https://doi.org/10.1200/JCO.2017.74.6651 CrossRefPubMed

50.

Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman D, Ligibel J (2015) Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 33(10):1104–1111. https://doi.org/10.1200/JCO.2014.57.1547 CrossRefPubMed

51.

Carter J, Lacchetti C, Andersen BL, Barton DL, Bolte S, Damast S, Diefenbach MA, DuHamel K, Florendo J, Ganz PA, Goldfarb S, Hallmeyer S, Kushner DM, Rowland JH (2018) Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. J Clin Oncol 36(5):492–511. https://doi.org/10.1200/JCO.2017.75.8995 CrossRefPubMed

52.

Hayes RD, Dennerstein L, Bennett CM, Sidat M, Gurrin LC, Fairley CK (2008) Risk factors for female sexual dysfunction in the general population: exploring factors associated with low sexual function and sexual distress. J Sex Med 5(7):1681–1693. https://doi.org/10.1111/j.1743-6109.2008.00838.x CrossRefPubMed

53.

Brotto L, Atallah S, Johnson-Agbakwu C, Rosenbaum T, Abdo C, Byers ES, Graham C, Nobre P, Wylie K (2016) Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med 13(4):538–571. https://doi.org/10.1016/j.jsxm.2016.01.019 CrossRefPubMed

54.

Reichenpfader U, Gartlehner G, Morgan LC, Greenblatt A, Nussbaumer B, Hansen RA, Van Noord M, Lux L, Gaynes BN (2014) Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf 37(1):19–31. https://doi.org/10.1007/s40264-013-0129-4 CrossRefPubMed

55.

Saha P, Regan MM, Pagani O, Francis PA, Walley BA, Ribi K, Bernhard J, Luo W, Gomez HL, Burstein HJ, Parmar V, Torres R, Stewart J, Bellet M, Perello A, Dane F, Moreira A, Vorobiof D, Nottage M, Price KN, Coates AS, Goldhirsch A, Gelber RD, Colleoni M, Fleming GF, SOFT; TEXT Investigators; International Breast Cancer Study Group (2017) Treatment efficacy, adherence, and quality of life among women younger than 35 years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trials. J Clin Oncol 35(27):3113–3122. https://doi.org/10.1200/JCO.2016.72.0946 CrossRefPubMedPubMedCentral

56.

Jeffery DD, Tzeng JP, Keefe FJ, Porter LS, Hahn EA, Flynn KE, Reeve BB, Weinfurt KP (2009) Initial report of the cancer Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function committee: review of sexual function measures and domains used in oncology. Cancer 115(6):1142–1153. https://doi.org/10.1002/cncr.24134 CrossRefPubMedPubMedCentral

57.

American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington DCCrossRef

58.

World Health Organization (2004) International classification of diseases and health related problems. World Health Organization, Geneva

59.

Hendrickx L, Gijs L, Enzlin P (2013) Distress, sexual dysfunctions, and DSM: dialogue at cross purposes? J Sex Med 10(3):630–641. https://doi.org/10.1111/j.1743-6109.2012.02971.x CrossRefPubMed

60.

Safarinejad MR, Shafiei N, Safarinejad S (2013) Quality of life and sexual functioning in young women with early-stage breast cancer 1 year after lumpectomy. Psychooncology 22(6):1242–1248. https://doi.org/10.1002/pon.3130 CrossRefPubMed

61.

Razdan SN, Patel V, Jewell S, McCarthy CM (2016) Quality of life among patients after bilateral prophylactic mastectomy: a systematic review of patient-reported outcomes. Qual Life Res 25(6):1409–1421. https://doi.org/10.1007/s11136-015-1181-6 CrossRefPubMed

62.

Bai L, Arver B, Johansson H, Sandelin K, Wickman M, Brandberg Y (2019) Body image problems in women with and without breast cancer 6–20 years after bilateral risk-reducing surgery–a prospective follow-up study. Breast 44:120–127. https://doi.org/10.1016/j.breast.2019.01.013 CrossRefPubMed

Title: Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy
Authors: Karin Ribi
Weixiu Luo
Barbara A. Walley
Harold J. Burstein
Jacquie Chirgwin
Rafat H. Ansari
Muhammed Salim
Andre van der Westhuizen
Ehtesham Abdi
Prudence A. Francis
Stephen Chia
Vernon J. Harvey
Anita Giobbie-Hurder
Gini F. Fleming
Olivia Pagani
Angelo Di Leo
Marco Colleoni
Richard D. Gelber
Aron Goldhirsch
Alan S. Coates
Meredith M. Regan
Jürg Bernhard
Publication date: 01-06-2020
Publisher: Springer US
Keywords: Mood Disorders
Breast Cancer
Affective Disorder
Breast Cancer
Cytostatic Therapy
Tamoxifen
Exemestane
Published in: Breast Cancer Research and Treatment / Issue 2/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05622-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

Financial toxicity and its associated patient and cancer factors among women with breast cancer: a single-center analysis of low-middle income region in China

Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer

Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts

Association of body composition with function in women with early breast cancer

Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis

Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer